Skip to main content

Individual Drug Analyses

This page contains a complete list of all FDA analyses conducted in the Sentinel System from the start of Mini-Sentinel in 2009 to the present. 

The table below is organized at the individual analysis level (e.g., Level 1, Level 2, Query Builder, protocol-based assessment, etc.). It is designed to support searches for a specific analysis. 

Alternatively, the Drug Studies table groups together related analyses that FDA conducted to address a safety concern, or set of related safety concerns. The Drug Studies page also provides important background information and describes the regulatory impact.

Note: The appearance of a drug in a Sentinel study does not mean that FDA has concluded that a causal relationship exists between the drug and the health outcome of interest. Patients and healthcare providers should refer to FDA.gov for further information about drug safety.

FDA Sentinel Analyses from ARIA and Other Sentinel Data Sources

Title Medical Product Outcomes Date
Characterization of Confounding Covariates in the TriNetX: A Descriptive Analysis
Descriptive
Utilization Patterns of Single and Multiple Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis
Descriptive
multiple inhaler triple therapy (MITT),
single inhaler triple therapy (SITT)
Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: A Third Descriptive Analysis
Descriptive
Gimoti (metoclopramide nasal spray)
Valsartan and Non-Valsartan Angiotensin Receptor Blocker Utilization in Denmark Following Recalls Due to Nitrosamine Impurities: A Descriptive Analysis
Descriptive
non-valsartan angiotensin receptor blockers,
valsartan
switching patterns
Valsartan and Non-Valsartan Angiotensin Receptor Blocker Utilization in the United Kingdom Following Recalls Due to Nitrosamine Impurities: A Descriptive Analysis
Descriptive
non-valsartan angiotensin receptor blockers,
valsartan
switching patterns
Valsartan and Non-Valsartan Angiotensin Receptor Blocker Utilization in Canada Following Recalls Due to Nitrosamine Impurities: A Descriptive Analysis
Descriptive
non-valsartan angiotensin receptor blockers,
valsartan
switching patterns
Valsartan and Non-Valsartan Angiotensin Receptor Blocker Utilization in the United States Following Recalls Due to Nitrosamine Impurities: A Descriptive Analysis
Descriptive
non-valsartan angiotensin receptor blockers,
valsartan
switching patterns
Duration of Follow Up for New Molecular Entities Approved in 2022: First Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Prescriptions and Dispensings of Central Nervous System (CNS) Stimulants: A Descriptive Analysis
Descriptive
central nervous system stimulants
Utilization Patterns of Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis
Descriptive
multiple inhaler triple therapy (MITT),
single inhaler triple therapy (SITT)